摘要
目的观察质子泵抑制剂(proton pump inhibitor,PPI)联合FOLFOX方案用于Ⅱ、Ⅲ期结肠癌术后辅助化疗的价值。方法选取本院2010年1月至2012年1月86例Ⅱ、Ⅲ结肠癌患者,随机分为观察组与对照组,每组各43例。观察组于术后4 w内应用PPI联合FOLFOX方案,对照组仅应FOLFOX辅助化疗。采用免疫组化法观察结肠癌患者的V-ATPase表达,比较两组患者随访2年、3年、5年的无病生存率(Disease-free survival,DFS)及化疗不良反应发生率。结果观察组与对照组V-ATPase阳性率分别为67.44%、74.42%(P>0.05)。观察组2年、3年、5年DFS率分别为76.74%、65.12%、55.81%,对照组为58.14%、48.84%、39.53%,差异无统计学意义(P>0.05)。观察组Ⅲ期患者的2年DFS率为78.26%,高于对照组(P<0.05),V-ATPase阳性患者的2年、3年DFS率分别为75.86%、65.52%,均高于对照组(均P<0.05),Ⅱ期患者DFS率比较差异均无统计学意义(均P>0.05)。结论 PPI联合FOLFOX方案可在一定程度上延长Ⅲ期结肠癌及V-ATPases阳性患者根治术后的DFS,使患者远期获益。
Objective To study the effect of PPI combined with FOLFOX regimen as postoperative adjuvant chemotherapy for stage Ⅱ and Ⅲ colorectal cancer. Methods 86 patients with colon cancer were recruited from January 2010 to January 2012 in our hospital and were randomly assigned to treatment group and control group, with 43 cases in each group. The treatment group was treated with PPI combined with FOLFOX regimen within 4 weeks after operation, and the control group with FOLFOX regimen. The expression of V-ATPase was measured by immunohistochemistry. The disease free survival（DFS） of followed up for 2 years, 3 years, 5 years and adverse events of chemotherapy were compared between two groups. Results The positive rates of V-ATPase in the treatment group and the control group were 67.44% and 74.42%, respectively（P〉0.05）. The 2-year, 3-year, and 5-year DFS rates were 76.74%,65.12%, 55.81%, respectively, in treatment group and 58.14%, 48.84%, 39.53% in control group, respectively（P〉0.05）. The 2-year DFS rate of stage Ⅲ colorectal cancer in the treatment group was 78.26%, which was higher than that in the control group（P〈0.05）.The 2-year and 3-year DFS rates of V-ATPase-positive patients in the treatment group were 75.86% and 65.52%, respectively, which were significantly higher than those in the control group（P〉0.05）. There was no significant difference in DFS rate between the two groups in stage Ⅱ patients（P〉0.05）. Conclusion PPI combined with FOLFOX regimen can improve the DFS of patients with stage Ⅲ colorectal cancer and V-ATPases positive patients, with favorable long-term efficacy.
出处
《结直肠肛门外科》
2017年第5期587-591,共5页
Journal of Colorectal & Anal Surgery
作者简介
通信作者
